Bendamustine impairs humoral but not cellular immunity to SARS-CoV-2 vaccination in rituximab-treated B-cell lymphoma–affected patients

Bendamustine impairs humoral but not cellular immunity to SARS-CoV-2 vaccination in rituximab-treated B-cell lymphoma–affected patients

BackgroundPatients with B-cell lymphoma are a fragile category of subjects, particularly exposed to infections and characterized by an impaired vaccination response due to the disease itself and, even more, to the chemotherapy regimen. For this reason, extensive knowledge of the immune response stat...

Full description

Bibliographic Details
Main Authors: Anna Vanni, Lorenzo Salvati, Alessio Mazzoni, Giulia Lamacchia, Manuela Capone, Stefania Francalanci, Seble Tekle Kiros, Lorenzo Cosmi, Benedetta Puccini, Manuel Ciceri, Benedetta Sordi, Gian Maria Rossolini, Francesco Annunziato, Laura Maggi, Francesco Liotta
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-12-01
Series:Frontiers in Immunology
Subjects:
SARS-CoV-2
mRNA vaccine
B cell lymphoma
anti-CD20mAb
rituximab
bendamustine
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1322594/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1322594/full

Similar Items